drugset
drugset / Trial / NCT01851174

Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer

NCT01851174 ↗

Phase 2 Terminated 15 enrolled Western Regional Medical Center
NaSingle-groupOpen-labelTreatment

Summary

To determine whether the occurrence of adverse events can be decreased by moving to a bi-weekly schedule of gemcitabine plus nab-Pacitaxel for the treatment of unresectable/metastatic pancreatic cancer.

Timeline

Start
2013-02
Primary completion
2015-01
Completion
2015-01

Outcome

Outcome not reported

Stopped: “PI Leaving Site”

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule 1000 mg/m2 Intravenous
Subject Nab-paclitaxel Small molecule 125 mg/m2 Intravenous

Indications

carcinoma pancreas disorder